Alzheimer's & Dementia: Detecting retinal amyloid in clinical trials may help pAD diagnosis

The development of biomarkers has focused on the detection of abnormal amyloid deposits in the brain during the preclinical (pAD) stage of Alzheimer's disease
.

For work aimed at therapeutic interventions for pAD, identifying asymptomatic subjects who are positive for amyloid is essential

Currently approved pAD biomarkers include amyloid ligand positron emission tomography (PET) and cerebrospinal fluid (CSF) amyloid levels.

The retina, known as the "window of the brain", exhibits pathological features similar to those of the brain in neurodegenerative disease states because they all originate from the same embryonic precursor
.

Standard clinical retinal evaluations of patients with neurodegenerative diseases, including AD, showing changes in retinal tissue and blood vessels , support this claim

The retina called the "window of the brain" will show pathological features similar to the brain in a neurodegenerative disease state.

In a recent small cross-sectional study, researchers compared retinal and brain amyloid levels in clinically normal people
.

Through positron emission tomography (PET), researchers screened individuals with high amyloid levels in asymptomatic Alzheimer’s disease anti-amyloid treatment (A4) trials , as well as individuals with amyloid risk and nerves The Longitudinal Evaluation of Degeneration (LEARN) study screened out individuals with low levels

Screening

Comparison of retinal amyloid and brain amyloid

Comparison of retinal amyloid and brain amyloid

The researchers quantified the number of curcumin-positive fluorescent retinal spots in a small number of participants in the two studies to determine the retinal amyloid deposits at baseline
.

The results showed that the four participants in the A4 trial showed a greater number of retinal spots than the four participants in the LEARN study
.

The researchers observed a positive correlation between retinal spots and brain amyloid , which was measured by the normalized uptake ratio (SUVr)

Compared with the four participants in the LEARN study, the four participants in the A4 trial showed a greater number of retinal spots.

Support the use of retinal fundus imaging to detect amyloid deposits associated with brain amyloid PET SUVr Support the use of retinal fundus imaging to detect amyloid deposits associated with brain amyloid PET SUVr

 

Original source:

Original source:

Jennifer Ngolab et al.

Jennifer Ngolab et al.

 

Leave a message here